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INTRODUCTION: 
Leucoderma is the most common chronic depigmentation 
disorder or hypopigmentation disorder affecting 1-2% of 
the world population
1
. It includes the loss of functioning 
melanocytes which causes the appearance of white patches 
on the skin
2
. These white patches tend to become 
progressive with time
3
. Any location on the body can be 
affected and the people with leucoderma have white 
patches in many areas of the body
4
. The disorder affects all 
the races and both the sexes equally; however, it is more 
noticeable in people with dark skin
5
. 
Although leucoderma is usually not harmfu l medically and 
causes no physically pain, its emot ional and psychological 
effects can be devastating
6
. Infact, in India, those with the 
disease, especially women, are sometimes discriminated 
against in marriage. Developing leucoderma after marriage 
can be ground for divorce. Regardless of person’s race and 
culture, white patches of leucoderma can affect emotional 
and psychological well-being and self-esteem. People with 
leucoderma can experience emotional stress, particularly if 
the condition develops on the visible areas of the body 
(such as face, hands, arms and feet) or on the genitals. 
Adolescents, who are part icularly concerned about their 
appearance, can be devastated by widespread leucoderma. 
Some people who have leucoderma feel embarrassed, 
ashamed, depressed or worried about how others will 
react
7
. 
 Leucoderma can be classified into two types
8, 9
: 
1).Bilateral (or Generalized): 
Bilateral or Generalized Leucoderma can begin at any age 
and tends to progress intermittently over the life of the 
patient. It produces depigmentation which is remarkably  
symmytrical in distribution. A patch on the right side of 
the body is matched by a patch in a similar location on the 
left side of the body. The entire body can depigment 
although it rarely does so. 
2).Unilateral (or Segmental): 
Unilateral or Segmental Leucoderma commonly begins in 
childrens and young adults and progresses for a limited 
period, usually 1-2 years, and then remains static for the 
rest of the life of the individual. It affects just one side of 
the body contrast to Bilateral Leucoderma, the distribution 
is asymmetrical on the skin. 
MELANIN PIGMENT: 
Melanins are polymorphous and multifunctional 
biopolymers. It includes eumelanin, pheomelanin, 
neuromelan in and mixed melan in pigment (shown in 
figure 1)
10
. 
Intact mature melanosomes pass from basal melanocytes 
into keratinocytes and their lysosomal compartment to 
become melanin dust in the upper nonviable layers of the 
skin
11
. Melanin is synthesized by melanocytes within 
melanosomes that are transferred into the surrounding 
keratinocytes
12
. The keratinocytes transport the melanin  
and melanosomes from the basal layer of the epidermis to 
the stratum corneum where they are desquamated into the 
environment (as shown in figure. 2)
13
.
 
ABSTRACT:  
Leucoderma is an acquired cutaneous disorder of pigmentation, with an incidence of 1% to 2% worldwide. There 
are many hypotheses for the pathogenesis of leucoderma. Recent data provide strong evidence supporting an 
autoimmune pathogenesis of leucoderma. Leucoderma can have major effect on quality of life. Topical therapy is 
employed as first-line treatment in localized leucoderma. Plants have been the basis of many traditional medicines 
throughout the world for thousands of years and continue to provide new remedies to mankind. The recent 
resurgence of plant remedies resulted from several factors, such as effectiveness of plant medicines and lesser side 
effects compared with modern medicines. Psoralen containing plants have been used for centuries in popular 
medicine to treat leucoderma. Further advancement in treatments using different derivatives of psoralen molecules 
may result in decrease possibility of long-term side effects such as cutaneous malignancies. In this review we wish 
to present a detailed investigation on various herbs that can be used for the treatment of leucoderma.  
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Figure 1: Biosynthesis of Melanin Pigment
10 
 
 
Figure 2: Factors Regulating Mammalian Melanogenesis
13 
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PATHOPHYS IOLOGY OF LEUCODERMA:
 
There are two basic mechanisms whereby the skin can 
become white
14
. Some disorders inhibit or retard the 
production of melan in formation and the skin develops 
hypopigmentation
15
. Such disorders include, among many 
others, oculocutaneous albinism, pityriasis alba, tinea 
vesicolor and nevus depigmentosus
16
. In these disorders, 
melanocytes are present in normal numbers in the 
epidermis but produce less than normal amounts of 
melanin. Typically the skin exhib its mild to marked  
hypopigmentation. 
In contrast, other types of leucoderma are characterized by 
the absence of melanocytes and therefore, complete 
absence of melan in. Such d isorders include piebaldis m, the 
leucoderma of lupus erythematosus and other scarring 
disorders and vitiligo. These types of leucoderma typically  
are totally depigmented. Vitiligo and lupus cause a 
destruction of melanocytes during postnatal life. 
Piebald ism affects the migration of melanocytes during 
embryogenesis and the infant is born with depigmenattion 
of the hair and skin. The et iology of leucoderma is poorly 
understood. Various factors (stress, trauma, exposure to 
sunlight, infections, malignancies, neural abnormalit ies, 
melatonin, receptor dysfunction, impaired melanocyte 
migrat ion, some drugs, endocrine disease and cytotoxic 
compounds) have been implicated in the development of 
leucoderma. Despite these various factors the exact cause 
of leucoderma remains unclear. Many theories
17
 
(biochemical theory, cytotoxic theory, oxidant-antioxidant 
theory, neural theory, viral theory, autoimmune theory, self 
destruct theory, growth factor theory and convergence 
theory)
 
have been proposed to explain this disorder along 
with factors (as shown in table 1). 
 
Table 1: Research Work on Leucoderma Skin 
S.NO STUDY ON VITILIGO SKIN SHOWS REFERNCE 
1 Decreased Level of VIT1 mRNA 
Elevated Level of MSH-6 
18 
2 Increased Area of Rough Endoplasmic Reticulum 19 
3 Increased Level of T Cells 
Increased Level of Macrophages  
20 
4 Presence of High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes(CTL’s) 21 
5 Increased Level of Th 17 Cells 
Increased Level of Activated Dendritic Cells  
22 
 
TREATMENT AVAILABLE FOR LEUCODERMA: 
In general topical monotherapy is indicated for mild  to 
moderate vitiligo
23,24
. Current treatment options for vitiligo 
include medical, surgical and additional treatments
25,26
. 
Medical treatment targets the immune system and helps to 
arrest the spread of depigmentation
27,28
. In cases of stable 
vitiligo, repigmentation can be achieved by 
dermatosurgical techniques and additional includes use of 
cosmetics
29,30
. Both surgical and medical t reatment have 
their own limitations. Additional can only cover the patch 
and can be used along with surgical and medical 
treatments
31
. 
A).Medical Therapies 
1).Topical Steroid Therapy: Topical steroids are useful 
for the treatment of localized leucoderma. Marked or 
almost complete repigmentation can be obtained with 
potent corticosteroids (betamethasone, valerate, 
triamcinolone) and very potent corticosteroids (clobetasol, 
fluticasone propionate). 
2).Psoralen Photochemotherapy 
a).Topical Psoralen Photochemotherapy: Topical PUVA 
(Psoralen Plus UltraVio let light A) includes lower 
cumulat ive UVA doses than oral PUVA and lack of ocular 
and systemic toxicity. Low concentrations of psoralens 
should be used. The patient should be exposed to UVA 
approximately 20 to 30 minutes after application of the 
topical preparation. Following treatment the area is 
washed, a broad-spectrum sunscreen is applied and 
excessive sun exposure is avoided for at least 24 hours.  
b).Oral Psoralen Photochemotherapy: Oral PUVA 
involves the admin istration of psoralens orally followed by 
exposure to long-wavelength UVA irradiat ion. 
3).Depigmentation: Depigmentation is a more drastic 
form of treatment, when leucoderma is extensive i.e. 
leucoderma universalis. Depigmentation involves fading 
the rest of the skin on the body to match the already white 
areas by using permanent melanocytotoxic agents such as 
Monobenzyl ester of hydroquinone cream (Benzoquin), 4-
methoxyphenol (4-MP). 
B).Surgical Therapies  
1).Autologous Skin Grafts: In this technique grafts are 
implanted into perforations prepared at the recipient sites. 
Pigment spread leading to repigmentation can be 
stimulated by phototherapies. 
2).Skin Grafts Using Blisters: In this technique blisters 
can be induced by different ways such as vacuum or liquid  
nitrogen. The mechanical split occurs at the 
dermoepidermal junction. The recipient site is prepared by 
dermabrasion. The graft is applied and secured on the 
recipient site. 
3)Micropigmentation (Tattooing): In this technique 
permanent dermal micropigmentation is done by using a 
nonallergic iron oxide pigment to camouflage recalcitrant 
areas of leucoderma.  
4).Autologous Melanocyte Trans plant: In th is technique 
noncultured keratinocyte-melanocyte suspensions obtained 
from a shave biopsy of the buttock or full-thickness biopsy 
Kaur et al                                       Journal of Drug Delivery & Therapeutics; 2012, 2(3): 53-59    56 
© 2011, JDDT. All Rights Reserved                                                   ISSN: 2250-1177                                             CODEN: JDDTAO  
of the scalp and Melanocytes obtained from the hair 
follicles and interfollicu lar epidermis and keratinocytes are 
placed into a suspension for direct applicat ion to the 
recipient site without expansion in culture. 
C).Additional  Therapies  
1).Sunscreen: Leucodermic skin is more susceptible to 
sunburn and long term photodamage. To prevent sun-
induced darkening of the surrounding normal skin, broad 
spectrum high protection factor sunscreens (SPF15-30) 
which provide protection from UVB and UVA light should 
be used. 
2).Cosmetic: Camouflage is often used to cover affected 
areas. This may be practical for patients that have minimal 
disease or segmental disease. 
NATURAL FURANOCOUMARINS AS 
TREATMENT FOR LEUCODERMA: 
Psoralens belong to a group of heterocyclic compounds, 
the furanocoumarins, which are found in four or five major 
plant families. The umbelliferae and rutacae are the largest 
and most important of these; the leguminosae and 
moraceae include few but widely distributed species. 
Chemical structures of Psoralen and Isopsoralen are 
described (as shown in the figure. 3)
59 
 
Psoralen                                           Isopsoralen 
Figure 3: Chemical structures of Psoralen and Isops oralen
59 
Many familiar edible plants as celery, figs, caraway, 
lemon, etc., contain psoralens. As such, psoralens are 
components, in normal d iet, and they may even play a role 
in the physiology and biochemistry of normal human skin. 
It is of interest to mention that psoralens are found in many 
herbal remedies that have been employed for centuries
32,33
. 
Furanocoumarins are synthesized when the furan ring is 
built on a suitably substituted coumarin derivative. A furan 
ring can be condensed with a coumarin molecule in 12 
different ways and each of the resulting compounds can 
become the parent of a family of psoralen-like derivatives. 
Only those with a linear tricyclic structure resembling that 
of psoralen are active, potent photosensitizers. Those with 
a non-linear structure (angular nodes) like that of iso-
psoralen and iso-pseudo-psoralen are inactive
34,35
. The 
mechanis m of repigmentation of leucoderma patches under 
psoralen therapy cannot be clearly defined in the light of 
the available knowledge of the cause of leucoderma. 
However, it may be justifiab le to suggest that one or more 
of the following mechanis ms may operate in the process of 
repigmentation of leucoderma
36,37
: 
1). Through the increased tolerance to sun, and ultraviolet 
rays psoralens permit much longer solar or ultraviolet light 
irradiation and thus allow stronger stimulation to the 
melanocytes. 
2). Dopa positive melanocytes have been claimed to be 
present in the so-called relative leucoderma. 
Repigmentation may occur in areas having melanocytes 
that still retain, although slightly, dopa positively but not in 
areas having no dopa positive melanocytes. Psoralens may 
bring about stimulation of these weak dopa positive 
melanocytes to be actively engaged in melanogenesis. 
3). Psoralens may induce migrat ion of active melanocytes 
from the surrounding normal epidermis or hair 
melanocytes, lead to colonization of the depigmented areas 
by the melanocytes of the pigmented hair bulb.  
4). Psoralens may correct the ultrastructural abnormalit ies 
of the leucoderma melanocytes. 
Table 2: Reported Herbs that are claimed to be used in the condition of Leucoderma 
S.No Biological Name of The 
Plant 
Family Common Name Active Chemical Constituent Ref 
1 Albizzia lebbek Black ebony Fabaceae  Saponins, stigmastadienone 58 
2 Aloe barbadensis Aloes  Aloeaceae  Antraquinone glycosides 55 
3 Alstonia scholaris Indian devil t ree Apocyanaceae  Hallucinogenic indole alkalo ids  55 
4 Althaea officinalis Marshmallow  Malvaceae  Altheacoumarin g lycosides 42 
5 Ammi majus Ammi  Umbelliferae  Furanocoumarins  41,52 
6 Ammi visnaga Khella  Umbelliferae  Furanocoumarins  52 
7 Angelica sinensis Dong quai Umbelliferae  Ferulic acid 57 
8 Apium graveolens Celery  Umbelliferae  Furanocoumarins  43 
9 Arisaema amurense Tian nan xing Araceae  Diacy lglycerlgalactoside  57 
10 Aristolochia bracteata Bracteated 
birthwort  
Aristolochiaceae  Anthraquinones  56 
11 Astragalus membranaceus Astragalus  Fabaceae  Saponins, flavonoids 57 
12 Atractylodes japonica Japanese Compositae  Patchoulene  57 
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atractylodes 
13 Azadirachta indica Neem  Meliaceae  Azadirachtinol, nimbosterol 51,52 
14 Bambusa arundinaceae Bamboo  Bambusaceae  Polyuronides, pentosans 53 
15 Bituminaria bituminosa Arabian pea Fabaceae  Furanocoumarins  44 
16 Carthamus tinctorius Safflower  Compositae  Phenols, flavonoids 57 
17 Cassia angustifolia Senna leaf Leguminosae  Anthraquinone glycosides 42 
18 Cassia occidentalis Coffee senna Caesalpiniaceae  Anthraquinone glycosides 57 
19 Citrullus colocynthis Wild gourd Cucurbitaceae  Saponins, phytosterol glycosides, 
alkaloids 
58 
20 Citrus limonia Rangpur  Rutaceae  Furanocoumarins  43 
21 Cnidium officinale Chunkung  Umbelliferae Butlyidenephthalide  57 
22 Codonopisis pilosula Dang shen Campanulaceae  Hesperidin, alpha spinosterol, 
beta spinosterol 
57 
23 Cuscuta chinensis Chinese dodder Fabaceae  Quercetin, kaemferol, hyperoside 57 
24 Dalbergia sissoo Dalberg ia  Fabaceae  Isoflavones, stigmasterols  53,58 
25 Daucus carota Wild carrot Umbelliferae  Furanocoumarins  38 
26 Diplotaenia damavandica Kozal  Umbelliferae  Furanocoumarins  43 
27 Eclipta alba Bhringraj  Asteraceae  Steroids, flavonoids 43 
28 Elaeagnus bockii ------------ Elaegnaceae  Furanocoumarins  43 
29 Ficus carica Common fig  Moraceae  Furanocoumarins  45 
30 Foeniculum vulgare Fennel  Umbelliferae  Furanocoumarins  39 
31 Gentiana scabra Chinese gentian Gentianaceae  Xanthones, picroside 57 
32 Ginko biloba Gingko  Ginkgoaceae  Furanocoumarins  46,52 
33 Glycyrrhiza glabra Liquorice  Fabaceae  Glycyrrh itin ic acid, flavonoids 42 
34 Helectoris isora Indian screw fruit  Sterculiaceae  Sitosterols, flavonoids 56 
35 Lawsonia inermis Henna  Lythraceae  Xanthones, glycosides 53 
36 Liquidambar formosana Formosan gum Hamamelidaceae  Beta-sitasterol, oleanolic acid  56 
37 Lyceum Chinese Wolfberry  Solanaceae  Beta-sitosterol,ferulic acid 56 
38 Malva sylvastris Tall mallow Malvaceae  Flavonoids, carotenoids, phenols 42 
39 Melia azadirach Kattu vembu Meliaceae Vanillic acid, melianol 55 
40 Milk thistle Marian thistle Asteraceae  Flavanolignan, triterpene 
glycosides 
52 
41 Mimosa pudica Lajwanti  Fabaceae  Alkaloids, tannins  53 
42 Murraya koenigii Curry leaf tree  Rutaceae  Terpines  53 
43 Nigella sativa Kalonji  Ranunculaceae  Glucoside melanthin metarb in  52 
44 Ocimum sanctum Tulsi  Lamiaceae  Eugenol, o leanolic acid  53 
45 Operculina turpenthum  Trivruth  Convolvulaceae  Coumarin, beta sitosterol 42 
46 Paeonia lactiflora Garden peony Ranunculaceae  Monoterpene glycoside, albiflo rin  57 
47 Pastinaca sativa Parsnip  Umbelliferae  Furanocoumarins  43 
48 Petroselinum crispum  Parsley  Umbelliferae  Furanocoumarins  41 
49 Picorrhiza kurroa Kutki  Scrophulariaceae  Picrosides  47,52,
57 
50 Plumbago indica Fire plant  Plumbaginaceae  Plumbagin, vanillic acid, beta 
sitosterol 
50 
51 Polygala tenuifolia Chinese senega  Polygalaceae  Presengenin, xanthones 57 
52 Polypodium leucotomos Golden polypody Polypodiaceae  Furanocoumarins  48 
53 Prunella vulgaris Selfheal  Lamiaceae  Phenols, tannins, saponins 57 
54 Prunus persica Peach  Rosaceae  Glycerides, sterols 57 
55 Psoralea corylifolia Babchi  Fabaceae   Furanocoumarins  40 
56 Ruta graveolens Herb of g race Rutaceae  Furanocoumarins  49 
57 Semecarpus anacardium Bhilwa  Anacardiaceae  Sterols, flavonoids, glycosides 50,52 
58 Solanum nigrum European black 
nightshade 
Solanaceae  Phenols, anthocyanidins 57 
59 Swertia chirata Indian gentian Gentianaceae  Xanthones, oleanolic acid  57 
60 Tecomella undulata Roheda  Bignoniaceae  Stigmasterol  54 
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CONCLUS ION: 
Furanocoumarins are biologically active natural 
compounds found main ly in p lants belonging to the 
Umbelliferae, Rutaceae, Apiaceae, Asteraceae, Fabaceae, 
Oleaceae, Moraceae, Thymeleaceae Families. 
Furanocoumarins forms monofunctional adducts which 
would less likely promote cutaneous malignancies as 
compared to bifunctional adduct. The application of 
psoralens and different derivatives of psoralens with 
potentially fewer acute side effects has been one of the 
most recent advancements in the treatment of leucoderma. 
Psoralen containing plants have been used for centuries in 
popular medicine to treat leucoderma, a skin disease 
characterized by lack of pigmentation. Further 
advancement in treatments using different derivatives of 
psoralen molecu les should strive to decrease the possibility 
of long term side effects such as cutaneous malignancies.  
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